Single in situ intratumoral low-dose shikonin hydrogel plus mild photothermal therapy elicits systemic antitumor immunity in immune-cold triple-negative breast cancer
Aug 2026· International Journal of Oncology· Vol 69, pp. 1-23· 0 citations· 79 references
Medicine
TL;DR
It is indicated that a single intratumoral administration of low-dose SHK-loaded hydrogel combined with mild PTT can induce potent systemic antitumor immunity, supporting the further development of localized SHK-based therapeutic strategies for the treatment of immune-cold tumors.
Abstract
Shikonin (SHK) possesses potent antitumor activity; however, its severe non-selective toxicity greatly limits the feasibility of conventional systemic administration for cancer therapy. Likewise, mild photothermal therapy (PTT) has intrinsic limitations, including inadequate induction of immunogenic cell death (ICD) and compensatory activation of immunosuppressive pathways, such as increased IDO1 activity and PD-L1 expression. In the present study, low-dose SHK and gold nanorods were co-encapsulated within a supramolecular hydrogel (mPECT) and administered by intratumoral injection to achieve localized combination therapy with mild PTT. Mild PTT rapidly triggered antitumor immune activation within the immunosuppressive tumor microenvironment, whereas SHK sustained this response by suppressing PTT-induced IDO1 activation and PD-L1 upregulation and by markedly enhancing ICD. The mPECT hydrogel enabled prolonged local retention and controlled release of SHK, minimizing rapid systemic exposure while preserving therapeutic efficacy at the tumor site. This localized combination of SHK and mild PTT elicited a robust adaptive antitumor immune response that not only inhibited primary tumor growth but also suppressed the progression of untreated distant tumors and generated durable antitumor immune memory. These findings indicate that a single intratumoral administration of low-dose SHK-loaded hydrogel combined with mild PTT can induce potent systemic antitumor immunity, supporting the further development of localized SHK-based therapeutic strategies for the treatment of immune-cold tumors.
Photodynamic therapy (PDT) can elicit antitumor immunity by inducing immunogenic cell death (ICD), making it an attractive option for postoperative local cancer treatment. However, in solid tumors, aberrant vasculature and an immunosuppressive microenvironment often restrict immune-cell infiltration, thereby weakening...
Photoimmunotherapy has recently emerged from photodynamic therapy (PDT) by leveraging the intrinsic immunogenic potential of PDT to stimulate the host immune system against cancer. An ideal photosensitizer (PS) should not only trigger efficient tumor regression but also elicit robust antitumor immunity, thereby prevent...
Ushasri Chilakamarthi, Souma Ghosh, Manne Naga Rajesh et al.· ACS Applied Bio Materials· 0 citations
Breast cancer, particularly triple-negative breast cancer (TNBC), remains a major therapeutic challenge because of aggressive tumor progression, systemic toxicity, rapid clearance of conventional chemotherapeutics, and multidrug resistance. The present study developed a biomimetic, redox-responsive liposomal theranosti...
M. B. Duza· Natural Resources for Human...· 0 citations
Photothermal therapy (PTT) is a local treatment that uses photothermal conversion agents (PTAs) to absorb light and produce heat in tumor tissue. The direct result is tumor ablation. At the same time, heat-damaged tumor cells may undergo immunogenic cell death (ICD). This process is often accompanied by the release of...
Xiu-Yu Wei, Chan Mo, Jia-Chen Chen et al.· Frontiers in Immunology· 0 citations
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, largely due to the limited efficacy of conventional systemic therapies. Herein, we report an injectable dynamic double-network hydrogel Gel@R/N, composed of poly(vinyl alcohol) and tannic acid crosslinked via dynamic boronate ester bond...
Xian-Fei Zhou, Rou-Ye Wang, Jin-Chao Zhao et al.· Journal of Controlled Releas...· 0 citations
Radiofrequency ablation (RFA) is a locoregional therapy for hepatocellular carcinoma (HCC). However, the long-term efficacy for RFA is severely compromised by recurrence driven by an immunosuppressive tumor microenvironment (TME). In this study, we identify mature regulatory dendritic cells (mregDCs) as a key immune-re...
Man Luo, Sui Zheng, Wan-Rong Luo et al.· Journal of Controlled Releas...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.